Then came SURMOUNT-1, in a 2022 follow-up study by NEJM , which tested tirzepatide (Mounjaro) in people with obesity
Furthermore, blood glucose fluctuations may cause fatigue, particularly if you take insulin or sulfonylureas alongside your GLP-1 medication
This multi-receptor approach is designed to produce greater weight reduction than dual or single agonists, as demonstrated in the 2023 phase 2 trial data
Notably, despite the upregulation of SOD1 in the high-ROS subgroup of ErbB2-positive breast cancer cells, normal cellular proliferation still relies on SOD1 activity, indicating its dual role in promoting cancer progression and maintaining basal metabolism [22]
This low dose is taken for 30 days, and it is not effective at lowering blood sugar